Cargando…

A Novel Co-Crystal of Bexarotene and Ligustrazine Improves Pharmacokinetics and Tissue Distribution of Bexarotene in SD Rats

Bexarotene (BEX), a specific retinoic acid X receptor (RXR) agonist granted by Food and Drug Administration (FDA) approval for the clinical treatment of T cell lymphoma, has now been found to exert pharmacological effects in the nervous system, with low bioavailability and poor cerebral distribution...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ren, Shuyue, Jiao, Lingtai, Yang, Shiying, Zhang, Li, Song, Junke, Yu, Haoying, Wang, Jingrong, Lv, Tingting, Sun, Lan, Lu, Yang, Du, Guanhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7598278/ https://www.ncbi.nlm.nih.gov/pubmed/32977470 http://dx.doi.org/10.3390/pharmaceutics12100906

Ejemplares similares

Bexarotene combined with lapatinib for the treatment of Cushing’s disease: evidence based on drug repositioning and experimental confirmation
por: Yu, Haoying, et al.
Publicado: (2020)

Photodegradation of Bexarotene and Its Implication for Cytotoxicity
por: Kryczyk-Poprawa, Agata, et al.
Publicado: (2021)

Comparison of the Efficacy and Safety of Bexarotene and Photo(Chemo)Therapy Combination Therapy and Bexarotene Monotherapy for Cutaneous T-Cell Lymphoma
por: Morita, Akimichi, et al.
Publicado: (2022)

The utility of bexarotene in mycosis fungoides and Sézary syndrome
por: Panchal, Manisha R, et al.
Publicado: (2015)

Preclinical PET Neuroimaging of [(11)C]Bexarotene
por: Rotstein, Benjamin H., et al.
Publicado: (2016)

Bexarotene-Induced Hypertriglyceridemia: A Case Report
por: Maminakis, Chris, et al.
Publicado: (2018)

Identification of Bexarotene as a PPARγ Antagonist with HDX
por: Marciano, David P., et al.
Publicado: (2015)

Development of Bexarotene Analogs for Treating Cutaneous T-Cell Lymphomas
por: Warda, Ankedo, et al.
Publicado: (2023)

Bexarotene Gel: A New Topical Therapy for Alopecia Areata
por: Rajiv, Mahajan, et al.
Publicado: (2010)

The emerging role of bexarotene in the treatment of Alzheimer’s disease: current evidence
por: Tousi, Babak
Publicado: (2015)

Bexarotene: A Rare Cause of Misleading Thyroid Function Tests
por: Pattan, Vishwanath, et al.
Publicado: (2020)

Cocrystal Prediction of Bexarotene by Graph Convolution Network and Bioavailability Improvement
por: Xiao, Fu, et al.
Publicado: (2022)

FRI511 Bexarotene: A Deceptive Cause Of Iatrogenic Hypothyroidism
por: Ghaith, Sarah, et al.
Publicado: (2023)

Early Treatment Critical: Bexarotene Reduces Amyloid-Beta Burden In Silico
por: Rosenthal, Joseph, et al.
Publicado: (2016)

Effectiveness of combined bexarotene and excimer laser treatment for folliculotropic mycosis fungoides
por: Furukawa, Fumina, et al.
Publicado: (2021)

High-Dose Thyroid Hormone Replacement in Bexarotene-Induced Central Hypothyroidism
por: Mathews, Tony, et al.
Publicado: (2021)

Remyelination varies between and within lesions in multiple sclerosis following bexarotene
por: Brown, J. William L., et al.
Publicado: (2022)

Bexarotene improves motor function after spinal cord injury in mice
por: Wang, Xingyu, et al.
Publicado: (2023)

Advanced-Stage Primary Cutaneous T-Cell Lymphoma Treated with Bexarotene and Denileukin Diftitox
por: Cervigón-González, Iván, et al.
Publicado: (2011)

Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma
por: Illidge, T, et al.
Publicado: (2013)

When the dust settles: what did we learn from the bexarotene discussion?
por: Tesseur, Ina, et al.
Publicado: (2013)

Correction: Early Treatment Critical: Bexarotene Reduces Amyloid-Beta Burden In Silico
por: Rosenthal, Joseph, et al.
Publicado: (2016)

Bexarotene targets autophagy and is protective against thromboembolic stroke in aged mice with tauopathy
por: Huuskonen, Mikko T., et al.
Publicado: (2016)

Bexarotene – a novel modulator of AURKA and the primary cilium in VHL-deficient cells
por: Chowdhury, Pratim, et al.
Publicado: (2018)

Influence of the Number of Axial Bexarotene Ligands on the Cytotoxicity of Pt(IV) Analogs of Oxaliplatin
por: Nosova, Yulia N., et al.
Publicado: (2017)

Efficacy and safety of bexarotene combined with photo(chemo)therapy for cutaneous T‐cell lymphoma
por: Morita, Akimichi, et al.
Publicado: (2020)

Drug screening identifies tazarotene and bexarotene as therapeutic agents in multiple sulfatase deficiency
por: Schlotawa, Lars, et al.
Publicado: (2023)

The rexinoid, bexarotene, prevents the development of premalignant lesions in MMTV-erbB2 mice
por: Li, Y, et al.
Publicado: (2008)

Bexarotene treatment does not clear β-Amyloid in an AD mouse model and Beagle dogs
por: Tesseur, Ina, et al.
Publicado: (2013)

Bexarotene Reduces Blood-Brain Barrier Permeability in Cerebral Ischemia-Reperfusion Injured Rats
por: Xu, Lu, et al.
Publicado: (2015)

Successful Treatment of Advanced Primary Cutaneous Peripheral T-Cell Lymphoma with Oral Bexarotene Monotherapy
por: Sato, Yota, et al.
Publicado: (2018)

Bexarotene normalizes chemotherapy-induced myelin decompaction and reverses cognitive and sensorimotor deficits in mice
por: Chiang, Angie C. A., et al.
Publicado: (2020)

Circular RNAs: Promising Molecular Biomarkers of Human Aging-Related Diseases via Functioning as an miRNA Sponge
por: Ren, Shuyue, et al.
Publicado: (2020)

Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer’s disease
por: Cummings, Jeffrey L., et al.
Publicado: (2016)

Synergistic effect of a retinoid X receptor-selective ligand bexarotene and docetaxel in prostate cancer
por: Shen, Danyang, et al.
Publicado: (2019)

Bexarotene Reduces Production of CCL22 From Tumor-Associated Macrophages in Cutaneous T-Cell Lymphoma
por: Tanita, Kayo, et al.
Publicado: (2019)

A case report: rapid progression of coronary atherosclerosis in a patient taking Targretin (Bexarotene)
por: DeAngelo, Sean, et al.
Publicado: (2020)

Bexarotene Impairs Cognition and Produces Hypothyroidism in a Mouse Model of Down Syndrome and Alzheimer’s Disease
por: Vidal, Verónica, et al.
Publicado: (2021)

Real-life Use of Bexarotene for T-cell Cutaneous Lymphoma Management: Efficacy and Tolerance with Low Doses
por: ROUANET, Jacques, et al.
Publicado: (2022)

CD25 expression could be a prognostic marker of bexarotene monotherapy for cutaneous T‐cell lymphomas
por: Yamamoto, Jun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_h1jtpa86h90iv80kr1n9n540ii